Compare Neurocrine Biosciences Inc (NBIX) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $38.55. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | QDTY | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $185.50 | $46.71 |
52-Week Low | $123.10 | $36.57 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
QDTY trades at $39.07, up 0.12% on the day, with a bearish technical signal driven by moving averages. The stock exhibits weekly dividend distributions, yet key valuation and profitability ratios are unavailable, limiting fundamental clarity. Recent news highlights consistent dividend announcements from YieldMax ETFs, indicating a focus on income generation.
The outlook hinges on forthcoming financial disclosures to assess sustainability; risks include reliance on dividend strategy amid missing fundamentals. Investors face uncertainty without earnings or revenue data, requiring caution until corporate performance metrics are published.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
